SHERWOOD, Ore., May 2, 2012 (GLOBE NEWSWIRE) -- Entia Biosciences, Inc. (OTCBB:ERGO) (ENTIA) has developed a new medical food for the treatment of Rheumatoid Arthritis (RA), a systemic autoimmune disease that causes pain, stiffness, swelling, and loss of function in the joints. RA affects roughly 1-2% of the world-wide population and occurs when a person's immune system mistakenly starts attacking healthy tissue, causing inflammation in the joints and a progressive loss of flexibility. If not managed properly, over time, RA can cause joint damage and can even result in permanent joint destruction.

ErgoD2™ Flex-RA is based on Entia's proprietary ErgoD2™ whole-food formulations that are 100% vegan and USDA certified organic. ErgoD2™ contains naturally high concentrations of the powerful antioxidants Ergothioneine and Ergocalciferol (Vitamin D2), which has been enhanced using Entia's patent pending UV light technology to safely increase vitamin D2 levels by greater than 1,000%. Vitamin D is an essential nutrient that helps maintain a healthy immune system and activates the cells that fight inflammation and infection. During the past decade, there's been an explosion of research suggesting that vitamin D additionally plays a significant role in joint health and that low levels may be a risk factor for rheumatologic conditions such as rheumatoid arthritis and osteoarthritis. According to a study presented at the 2008 European Union League Against Rheumatism (EULAR) meeting in Paris, nearly 75 percent of patients who presented at a rheumatology clinic, including those who were subsequently diagnosed with inflammatory joint diseases, soft-tissue rheumatism, uncomplicated musculoskeletal backache or osteoporosis, were deficient in vitamin D.

(0)

(0)

Investors Hangout

Whats Hot